Cantor Fitzgerald Estimates MannKind FY2025 Earnings

MannKind Co. (NASDAQ:MNKD - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for MannKind in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of $0.34 per share for the year. The consensus estimate for MannKind's current full-year earnings is $0.10 per share.

Several other brokerages have also weighed in on MNKD. Royal Bank of Canada upgraded shares of MannKind from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $7.00 to $10.00 in a report on Thursday, December 19th. StockNews.com lowered shares of MannKind from a "buy" rating to a "hold" rating in a report on Saturday, December 7th. Finally, Wells Fargo & Company began coverage on MannKind in a report on Friday, December 20th. They set an "overweight" rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, MannKind presently has an average rating of "Buy" and an average price target of $9.07.

MannKind Stock Down 3.6 %

Shares of MNKD traded down $0.22 during trading hours on Thursday, reaching $5.95. 2,632,030 shares of the company traded hands, compared to its average volume of 2,156,688. The stock has a market capitalization of $1.64 billion, a PE ratio of 85.00 and a beta of 1.29. The stock has a fifty day simple moving average of $6.51 and a 200 day simple moving average of $6.26. MannKind has a fifty-two week low of $3.17 and a fifty-two week high of $7.63.

MannKind (NASDAQ:MNKD - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.04 EPS for the quarter, meeting the consensus estimate of $0.04. The firm had revenue of $70.08 million during the quarter, compared to analysts' expectations of $77.27 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%.

Institutional Investors Weigh In On MannKind

Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. increased its holdings in shares of MannKind by 401.8% during the 3rd quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company's stock valued at $1,060,000 after acquiring an additional 134,937 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in MannKind during the third quarter worth approximately $12,252,000. Barclays PLC grew its holdings in MannKind by 186.0% during the third quarter. Barclays PLC now owns 519,865 shares of the biopharmaceutical company's stock valued at $3,271,000 after purchasing an additional 338,121 shares during the last quarter. International Assets Investment Management LLC raised its position in shares of MannKind by 511.6% in the third quarter. International Assets Investment Management LLC now owns 88,689 shares of the biopharmaceutical company's stock valued at $558,000 after purchasing an additional 74,189 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of MannKind by 37.1% in the third quarter. Parkman Healthcare Partners LLC now owns 3,304,085 shares of the biopharmaceutical company's stock worth $20,783,000 after buying an additional 894,486 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company's stock.

Insider Activity

In other MannKind news, insider Stuart A. Tross sold 55,000 shares of the company's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total value of $403,700.00. Following the transaction, the insider now owns 967,191 shares of the company's stock, valued at approximately $7,099,181.94. This represents a 5.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven B. Binder sold 67,536 shares of the business's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $6.89, for a total value of $465,323.04. Following the sale, the director now directly owns 1,075,026 shares in the company, valued at $7,406,929.14. This trade represents a 5.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 190,075 shares of company stock worth $1,325,587 over the last three months. Corporate insiders own 3.00% of the company's stock.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.